Close Menu

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.

Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.

News items for the in vitro diagnostics industry for the week of March 15, 2021.

The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.

R-Pharm, Illumina's strategic partner in Russia and the Commonwealth of Independent States (CIS), led the registration process with the Russian regulatory agency.

The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

The Helix Laboratory Platform is the first whole-exome sequencing platform to receive do novo authorization by the agency and paves the way for others.

Pages